Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in ...
Ophthalmologists perform a dilated fundus examination to diagnose retinal tears. Dilating drops widen the pupil to allow ...
Non-invasive eye scans allow doctors a zoomed-in, three-dimensional look beneath the eye's surface without causing discomfort ...
Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing ...
Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing ...
Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...
Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO. In the final episode, “Access and Evidence Gaps in Retinal ...
The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...
VEGF biosimilar has moved closer to European approval for several vision-threatening retinal diseases, including choroidal neovascularization.
The Sociable on MSN
Curing, not coping: Off-world manufacturing may hold the answer to retinal blindness
A wet floor sign you should’ve seen but kicked halfway across the room; your niece, two or three heads smaller than you, ...
Opus Genetics (IRD) rated Hold: valuation hinges on AAV gene therapy success. Track LCA5 Phase 3, 2026 data catalysts & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results